Dr. Altschuller brings over two decades of clinical and commercial biotechnology experience as the company grows its clinical pipeline to five autoimmune disease and oncology drug candidates. WALTHAM, Mass.
, Aug. 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc. today announced it has expanded its executive leadership team with the addition of Dr.
Susan Altschuller as Chief Financial Officer. "We are delighted that Susan has joined Dragonfly," said Bill Haney , co-founder and CEO of Dragonfly Therapeutics. "Her leadership growing successful biopharma companies comes at an exciting time as Dragonfly expands our clinical pipeline in autoimmune disease, oncology, and neuro-inflammatory disease.
Susan's powerful combination of financial, clinical and development experience will help drive our mission to help patients by inventing and commercializing leading immune-engaging therapeutics." Susan Altschuller Ph.D.
, MBA is a seasoned senior biopharma executive with more than two decades of strategic and financial leadership experience at leading pharmaceutical and biotechnology companies. Most recently, she served as the chief financial officer of Cerevel Therapeutics, a biotechnology company developing therapies for neuroscience diseases, until its acquisition by AbbVie earlier this month. Before Cerevel, Dr.
Altschuller was chief financial officer of ImmunoGen, supporting the oncology company's first commercial launch. Prior to ImmunoGen Dr. Altschuller worked at Alexion, where.